NATPARA
Peakparathyroid hormone
BLAINJECTIONINJECTABLE
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
NATPARA (parathyroid hormone) is hormone. First approved in 2015.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATPARA is a recombinant parathyroid hormone (PTH) injection approved for hypoparathyroidism management. It works by raising serum calcium through increased renal tubular reabsorption, enhanced intestinal absorption via vitamin D activation, and increased bone turnover. This is a biologic hormone replacement therapy for a rare endocrine disorder.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30), offering stable career opportunities in a niche rare disease space.
Mechanism of Action
hormone. Parathyroid hormone raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption (i.e., by converting 25-OH vitamin D to 1,25-OH 2 vitamin D) and by increasing bone turnover which releases calcium into the circulation.
Pharmacologic Class:
Parathyroid Hormone
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
Started May 2023
412 enrolled
Secondary HyperparathyroidismEnd Stage Kidney Disease
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1
Started Apr 2023
362 enrolled
Secondary HyperparathyroidismEnd-stage Kidney Disease (ESKD)
A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)
Started Jan 2018
93 enrolled
Hypoparathyroidism
Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism
Started Apr 2017
34 enrolled
Hypoparathyroidism
A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
Started Oct 2016
39 enrolled
Chronic HypoparathyroidismHypoparathyroidism
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.